A novel approach of platelet function test for prediction of attenuated response to clopidogrel.
Immature platelet
aggregometry
clopidogrel
ischemic stroke
Journal
Clinical hemorheology and microcirculation
ISSN: 1875-8622
Titre abrégé: Clin Hemorheol Microcirc
Pays: Netherlands
ID NLM: 9709206
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
4
6
2019
medline:
4
3
2020
entrez:
4
6
2019
Statut:
ppublish
Résumé
Elevated mean platelet volume (MPV) and immature platelet fraction (IPF) are predictive for vascular risk. Both can be associated with residual platelet reactivity. We aimed to explore associations among platelet characteristics and responder status in stroke patients on clopidogrel. Blood samples from 46 patients and 15 healthy subjects were analyzed for platelet count, MPV, IPF, large cell ratio (LCR) and high-fluorsecent immature platelet fraction (H-IPF). As a novelty, not only whole blood, but upper and lower half blood samples after 1-hour gravity sedimentation were analyzed. Platelet aggregometry was used for the whole blood and separated samples to explore area under the curve (AUC) in patients and controls. The AUC of the whole blood showed significant differences compared to the upper and lower samples separated after 1-hour sedimentation in patients and controls (p < 0.001 and p = 0.005 respectively). Remarkably, AUC measured in the upper samples in 59% of patients on clopidogrel were exceeding the therapeutic range suggesting that ascending platelets exert aggregation in the presence of ADP. This observation was associated with increased MPV and LCR in the upper samples (both p = 0.04). Patients on clopidogrel were characterized as responders and non-responders and the percentage of H-IPF was significantly higher among non-responders compared to controls in the upper samples (p = 0.04). The modified platelet function test may help to stratify patients with high residual platelet reactivity.
Sections du résumé
BACKGROUND
BACKGROUND
Elevated mean platelet volume (MPV) and immature platelet fraction (IPF) are predictive for vascular risk. Both can be associated with residual platelet reactivity. We aimed to explore associations among platelet characteristics and responder status in stroke patients on clopidogrel.
METHODS
METHODS
Blood samples from 46 patients and 15 healthy subjects were analyzed for platelet count, MPV, IPF, large cell ratio (LCR) and high-fluorsecent immature platelet fraction (H-IPF). As a novelty, not only whole blood, but upper and lower half blood samples after 1-hour gravity sedimentation were analyzed. Platelet aggregometry was used for the whole blood and separated samples to explore area under the curve (AUC) in patients and controls.
RESULTS
RESULTS
The AUC of the whole blood showed significant differences compared to the upper and lower samples separated after 1-hour sedimentation in patients and controls (p < 0.001 and p = 0.005 respectively). Remarkably, AUC measured in the upper samples in 59% of patients on clopidogrel were exceeding the therapeutic range suggesting that ascending platelets exert aggregation in the presence of ADP. This observation was associated with increased MPV and LCR in the upper samples (both p = 0.04). Patients on clopidogrel were characterized as responders and non-responders and the percentage of H-IPF was significantly higher among non-responders compared to controls in the upper samples (p = 0.04).
CONCLUSIONS
CONCLUSIONS
The modified platelet function test may help to stratify patients with high residual platelet reactivity.
Identifiants
pubmed: 31156147
pii: CH190580
doi: 10.3233/CH-190580
pmc: PMC6971826
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Clopidogrel
A74586SNO7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-369Références
Atherosclerosis. 2013 Dec;231(2):392-400
pubmed: 24267257
Pancreas. 2017 Jan;46(1):35-41
pubmed: 27984485
Blood. 2017 Nov 16;130(20):2171-2179
pubmed: 28972013
Clin Hemorheol Microcirc. 2002;27(2):149-53
pubmed: 12237484
Clin Hemorheol Microcirc. 2018;70(3):257-265
pubmed: 29710682
Clin Hemorheol Microcirc. 2013;53(1-2):71-9
pubmed: 22954635
Res Pract Thromb Haemost. 2018 Feb 19;2(2):188-198
pubmed: 30046721
Br J Haematol. 1982 Mar;50(3):509-19
pubmed: 7066203
Thromb Haemost. 2015 Aug 31;114(3):449-58
pubmed: 26293514
Eur Heart J. 2015 Dec 1;36(45):3202-10
pubmed: 26216931
J Thromb Thrombolysis. 2012 Feb;33(2):137-42
pubmed: 22198802
J Am Coll Cardiol. 2010 Sep 14;56(12):919-33
pubmed: 20828644
J Cell Biol. 2013 Jun 10;201(6):785-96
pubmed: 23751492
Crit Care. 2013 Aug 27;17(4):236
pubmed: 23998653
Curr Drug Targets. 2014;15(7):720-8
pubmed: 24845219
J Clin Pathol. 2008 Nov;61(11):1209-13
pubmed: 18955576
J Clin Pathol. 2006 May;59(5):523-5
pubmed: 16533954